Exploring 18FAlF-NOTA-octreotide PETMRI to Detect and Assess Carotid Artery Disease in Adults with Recent Stroke or TIA

What this Trial Is About

Researchers are evaluating the use of 18FAlF-NOTA-octreotide PETMRI to study inflammation in carotid artery plaques in patients who recently had a stroke or transient ischemic attack TIA in the carotid artery area. This study aims to see if the tracer uptake in affected and unaffected carotid arteries can predict future cerebrovascular events such as recurrent TIA, stroke, or other vascular problems. The trial is conducted as a Phase 2 study at University Hospitals Leuven and focuses on patients with at least 30% stenosis in the carotid artery. Participants receive a single intravenous injection of the radioactive tracer 18FAlF-OC, dosed at 4 MBqkg, followed by a saline flush. The study has two parts in the first, five patients undergo PETMRI scans at 60, 120, and 180 minutes after injection to refine the imaging protocol. In the second part, nineteen patients receive PETMRI at the optimal time point identified earlier. Both the symptomatic culprit and non-symptomatic carotid arteries are scanned. Participants will have a screening and baseline assessment, followed by the PETMRI imaging visit. They will be contacted by telephone for follow-up interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA. Researchers will measure the standardized uptake values SUV of the tracer in the carotid arteries as the primary outcome. Secondary outcomes include the prediction of recurrent cerebrovascular events, major cardiovascular events, and overall mortality during the three-year follow-up period.

[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease